Literature DB >> 9405449

TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis.

Y Chicheportiche1, P R Bourdon, H Xu, Y M Hsu, H Scott, C Hession, I Garcia, J L Browning.   

Abstract

The members of the tumor necrosis factor (TNF) family play pivotal roles in the regulation of the immune system. Here we describe a new ligand in this family, designated TWEAK. The mouse and human versions of this protein are unusually conserved with 93% amino acid identity in the receptor binding domain. The protein was efficiently secreted from cells indicating that, like TNF, TWEAK may have the long range effects of a secreted cytokine. TWEAK transcripts were abundant and found in many tissues, suggesting that TWEAK and TRAIL belong to a new group of widely expressed ligands. Like many members of the TNF family, TWEAK was able to induce interleukin-8 synthesis in a number of cell lines. The human adenocarcinoma cell line, HT29, underwent apoptosis in the presence of both TWEAK and interferon-gamma. Thus, TWEAK resembles many other TNF ligands in the capacity to induce cell death; however, the fact that TWEAK-sensitive cells are relatively rare suggests that TWEAK along with lymphotoxins alpha/beta and possibly CD30L trigger death via a weaker, nondeath domain-dependent mechanism.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9405449     DOI: 10.1074/jbc.272.51.32401

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  196 in total

Review 1.  Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors.

Authors:  B G Darnay; B B Aggarwal
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  How to induce involuntary suicide: the need for dipeptidyl peptidase I.

Authors:  E R Podack
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

Review 3.  Immunological basis in the pathogenesis and treatment of bladder cancer.

Authors:  David B Thompson; Larry E Siref; Michael P Feloney; Ralph J Hauke; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2014-11-13       Impact factor: 4.473

4.  Genetic ablation of TWEAK augments regeneration and post-injury growth of skeletal muscle in mice.

Authors:  Ashwani Mittal; Shephali Bhatnagar; Akhilesh Kumar; Pradyut K Paul; Shihuan Kuang; Ashok Kumar
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

Review 5.  Role of TWEAK in lupus nephritis: a bench-to-bedside review.

Authors:  Jennifer S Michaelson; Nicolas Wisniacki; Linda C Burkly; Chaim Putterman
Journal:  J Autoimmun       Date:  2012-06-22       Impact factor: 7.094

6.  TWEAK induces liver progenitor cell proliferation.

Authors:  Aniela Jakubowski; Christine Ambrose; Michael Parr; John M Lincecum; Monica Z Wang; Timothy S Zheng; Beth Browning; Jennifer S Michaelson; Manfred Baetscher; Manfred Baestcher; Bruce Wang; D Montgomery Bissell; Linda C Burkly
Journal:  J Clin Invest       Date:  2005-08-18       Impact factor: 14.808

7.  Effect of influenza vaccine on tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in older adults.

Authors:  Maryam Keshtkar-Jahromi; Min Ouyang; Marzieh Keshtkarjahromi; Samah Almed; Huifen Li; Jeremy D Walston; Rebeca Rios; Sean X Leng
Journal:  Vaccine       Date:  2018-03-13       Impact factor: 3.641

Review 8.  Emerging molecular mediators and targets for age-related skeletal muscle atrophy.

Authors:  Lemuel A Brown; Steve D Guzman; Susan V Brooks
Journal:  Transl Res       Date:  2020-03-10       Impact factor: 7.012

9.  Antibody deficiency associated with an inherited autosomal dominant mutation in TWEAK.

Authors:  Hong-Ying Wang; Chi A Ma; Yongge Zhao; Xiying Fan; Qing Zhou; Pamela Edmonds; Gulbu Uzel; Joao Bosco Oliveira; Jordan Orange; Ashish Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-14       Impact factor: 11.205

10.  Transient TWEAK overexpression leads to a general salivary epithelial cell proliferation.

Authors:  T Sugito; F Mineshiba; C Zheng; A P Cotrim; C M Goldsmith; B J Baum
Journal:  Oral Dis       Date:  2008-09-29       Impact factor: 3.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.